Seeking Alpha

Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead...

Morgan Stanley picks three biotechs worth buying: Biogen (BIIB), Celgene (CELG) and Gilead Sciences (GILD). The latter "offers 15-20% upside and the most attractive combination of fundamental positive drivers... 2012 events have the potential to meaningfully improve long-term cash flow visibility, driving multiple expansion and positive EPS revisions.”
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs